Navigation Links
Codexis Opens Singapore Laboratory
Date:10/24/2007

SINGAPORE, Oct. 24 /PRNewswire/ -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing processes, today announced the opening of Codexis Laboratories Singapore Pte. Ltd. (CLS). CLS is the company's first research facility in Asia, and is an expansion of the company's research and development operations in the U.S. and Europe. CLS will support the company's pharmaceuticals business in both the innovator and generics markets.

The Guest of Honor at the laboratory opening ceremony was Mr. S. Iswaran, Minister of State for Trade and Industry. Other guests included Chu Swee Yeok, Bio*One Chief Executive Officer, Alan Shaw, Ph.D., Codexis President and Chief Executive Officer, Thomas Baruch, Chairman of the Board and other members of the company's Board of Directors. Bio*One Capital led the Codexis Series D private financing round in August 2006.

"Our expansion to Singapore is a significant part of our global development strategy," Dr. Shaw said. "Singapore offers us access to a highly skilled workforce, proximity to our growing customer base in Asia, and a productive business environment as our company grows. Codexis Laboratories Singapore will play an important role in the development of new products serving our pharmaceuticals markets worldwide."

"We are pleased that Codexis, one of the top biocatalyst companies in the world, has chosen to set up its research facility in Singapore," said Mr. S. Iswaran. "This investment is indeed a strong endorsement for our ability to host such cutting-edge R&D activities, and will, no doubt, contribute to ensuring the long-term sustainability of our pharmaceuticals manufacturing sector."

"Bio*One is delighted to welcome Codexis to Singapore," said Ms. Swee-Yeok Chu. "Our investment in Codexis reflects Bio*One's strong support for innovative biomedical sciences companies with cutting-edge technology that will significantly impact the growth of the biomedical industry in Singapore. We are pleased to be able to play a role in Codexis' expansion plans in Asia to further the company's growth."

The 20,000-square foot research and development center is in the Galen, in the Science Park III area of Singapore. When fully staffed, it is expected to house up to 70 R&D and operations personnel.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Singapore: Cecilia Tan or Alicia Thong, Foreword Communications

Pte Ltd, cecilia@foreword.com.sg or alicia@foreword.com.sg, +65 6338-5918.

US: Justin Jackson, jjackson@burnsmc.com, Burns McClellan, work,

212-213-0006, cell, 917-535-3248 or Lyn Christenson,

lyn.christenson@codexis.com, 650-298-5368


'/>"/>
SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. TomoTherapy opens technical training center
3. Japanese telecom opens liason office at UW-Platteville
4. Test center for RFID capabilities opens next week
5. Eau Claire business-plan contest opens
6. GE Healthcare opens facility meant for 2,000 employees
7. Space Place opens new astronomy center
8. Research on fruit flies opens up possibilities for human treatments
9. Paper technology transfer center opens in Green Bay
10. Nanotech exhibit opens at UW-Madison
11. Doyles Japan trip opens doors and minds for Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):